There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cardiff Oncology (CRDF – Research Report), Aclaris Therapeutics (ACRS – Research Report) and Akoya Biosciences (AKYA – Research Report) with bullish sentiments.
Cardiff Oncology (CRDF)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cardiff Oncology today and set a price target of $15.00. The company’s shares closed last Monday at $1.72.
According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cardiff Oncology with a $15.00 average price target.
See today’s best-performing stocks on TipRanks >>
Aclaris Therapeutics (ACRS)
BTIG analyst Julian Harrison maintained a Buy rating on Aclaris Therapeutics yesterday and set a price target of $29.00. The company’s shares closed last Monday at $7.07.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of
Currently, the analyst consensus on Aclaris Therapeutics is a Strong Buy with an average price target of $33.00, representing a 334.2% upside. In a report issued on February 24, H.C. Wainwright also reiterated a Buy rating on the stock with a $50.00 price target.
Akoya Biosciences (AKYA)
BTIG analyst Mark Massaro reiterated a Buy rating on Akoya Biosciences today and set a price target of $18.00. The company’s shares closed last Monday at $11.15.
According to TipRanks.com, Massaro is a 1-star analyst with an average return of
Currently, the analyst consensus on Akoya Biosciences is a Moderate Buy with an average price target of $16.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRDF:
